Literature DB >> 14552564

Characteristics, management and outcome of patients with recurrent tuberculosis under routine programme conditions in Malawi.

F M Salaniponi1, T E Nyirenda, J R Kemp, S B Squire, P Godfrey-Faussett, A D Harries.   

Abstract

SETTING: All 43 non-private hospitals in Malawi, which registered TB cases between 1 July 1999 and 30 June 2000.
OBJECTIVES: To determine 1) the characteristics, management and treatment outcome, 2) timing of the previous episode of TB, and 3) pattern of drug resistance in patients registered with recurrent smear-positive pulmonary TB.
DESIGN: Retrospective data collection using TB registers and laboratory culture and drug sensitivity registers.
RESULTS: There were 748 recurrent patients; data were available for 747. Of these, 487 (65%) successfully completed a re-treatment regimen, 185 (25%) died and the remainder had another outcome. Information about previous TB was recorded for 491 (66%) patients. In 286 (58%) there were 2 years or less between completing and re-starting treatment. Only 307 (41%) patients had sputum sent for culture and drug sensitivity tests. In 164 patients with cultures of Mycobacterium tuberculosis, 122 (81%) were fully sensitive, 25 (15%) had resistance to isoniazid and/or streptomycin, and 6 (4%) had resistance to isoniazid and rifampicin (MDR-TB).
CONCLUSION: Patients with recurrent TB had acceptable treatment outcomes, and most had fully sensitive organisms. Over half had recurrent TB 2 years or less after completing treatment. Ways to prevent recurrence need to be investigated and implemented in the field.

Entities:  

Mesh:

Year:  2003        PMID: 14552564

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Prevalence of drug resistant TB among outpatients at an HIV/TB clinic in Lilongwe, Malawi.

Authors:  Brian Barnett; Runa H Gokhale; Robert Krysiak; Creto Kanyemba; Tarsizio Chikaonda; Mphatso Bokosi; Cornelius Mukuzunga; Friday Saidi; Sam Phiri; Irving F Hoffman; Mina C Hosseinipour
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-12       Impact factor: 2.184

2.  Evaluations of Factors Affecting of Short-and Long-Time of Occurrence of Disease Relapse in Patients with Tuberculosis Using Parametric Mixture Cure Model: A Cohort Study.

Authors:  Mehdi Kazempour-Dizaji; Mohammad Varahram; Payam Tabarsi; Rahim Roozbahani; Ali Zare; Mohammad Ali Emamhadi; Majid Marjani; Atefe Abedini; Afshin Moniri; Mohammadreza Madani; Parvaneh Baghaei Shiva
Journal:  Tanaffos       Date:  2022-01

Review 3.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

4.  Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Authors:  Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa
Journal:  PLoS Med       Date:  2011-03-15       Impact factor: 11.069

Review 5.  Prevalence of inappropriate tuberculosis treatment regimens: a systematic review.

Authors:  M W Langendam; M J van der Werf; E Huitric; D Manissero
Journal:  Eur Respir J       Date:  2011-10-17       Impact factor: 16.671

6.  Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China.

Authors:  Yanni Sun; David Harley; Hassan Vally; Adrian Sleigh
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

7.  A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.

Authors:  D B Cohen; J Meghji; S B Squire
Journal:  Int J Tuberc Lung Dis       Date:  2018-10-01       Impact factor: 2.373

8.  Underreported threat of multidrug-resistant tuberculosis in Africa.

Authors:  Yanis Ben Amor; Bennett Nemser; Angad Singh; Alyssa Sankin; Neil Schluger
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

9.  Poor outcomes in recurrent tuberculosis: More than just drug resistance?

Authors:  Danielle B Cohen; Geriant Davies; Wakisa Malwafu; Helen Mangochi; Elizabeth Joekes; Simon Greenwood; Liz Corbett; S Bertel Squire
Journal:  PLoS One       Date:  2019-05-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.